Hyderabad, India-based Aurobindo Pharma announced that its wholly owned subsidiary Eugia Pharma Specialties, received a final approval from the U.S. Food & Drug Administration to manufacture and market Leuprolide Acetate Injection.
This drug is used in palliative treatment of advance prostatic cancer. It had an estimated market size of $83 million for the twelve months ending April 2022, according to IQVIA, provider of advanced analytics, technology solutions. and clinical research services to the life sciences industry.
